List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6037505/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Maternal and prenatal factors and age at thelarche in the LEGACY Girls Study cohort: implications for breast cancer risk. International Journal of Epidemiology, 2023, 52, 272-283.	0.9	1
2	Smoking, Radiation Therapy, and Contralateral Breast Cancer Risk in Young Women. Journal of the National Cancer Institute, 2022, 114, 631-634.	3.0	6
3	OUP accepted manuscript. International Journal of Epidemiology, 2022, , .	0.9	0
4	Maternal prenatal psychological distress and vitamin intake with children's neurocognitive development. Pediatric Research, 2022, , .	1.1	0
5	Association of contralateral breast cancer risk with mammographic density defined at higherâ€thanâ€conventional intensity thresholds. International Journal of Cancer, 2022, 151, 1304-1309.	2.3	3
6	Evaluating depression and anxiety throughout pregnancy and after birth: impact of the COVID-19 pandemic. American Journal of Obstetrics & Gynecology MFM, 2022, 4, 100605.	1.3	17
7	Common Childhood Viruses and Pubertal Timing: The LEGACY Girls Study. American Journal of Epidemiology, 2021, 190, 766-778.	1.6	3
8	Prepubertal Internalizing Symptoms and Timing of Puberty Onset in Girls. American Journal of Epidemiology, 2021, 190, 431-438.	1.6	14
9	Comparing 5-Year and Lifetime Risks of Breast CancerÂusing the Prospective Family Study Cohort. Journal of the National Cancer Institute, 2021, 113, 785-791.	3.0	13
10	Race, ethnicity and risk of second primary contralateral breast cancer in the United States. International Journal of Cancer, 2021, 148, 2748-2758.	2.3	13
11	Coronary Artery Disease in Young Women After Radiation Therapy for Breast Cancer. JACC: CardioOncology, 2021, 3, 381-392.	1.7	31
12	Mammographic texture features associated with contralateral breast cancer in the WECARE Study. Npj Breast Cancer, 2021, 7, 146.	2.3	1
13	Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk. JNCI Cancer Spectrum, 2021, 5, pkab090.	1.4	1
14	Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results. Journal of the National Cancer Institute, 2020, 112, 418-422.	3.0	1
15	Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk. Cancer Research, 2020, 80, 116-125.	0.4	37
16	Association between maternal acetaminophen use and adverse birth outcomes in a pregnancy and birth cohort. Pediatric Research, 2020, 87, 1263-1269.	1.1	9
17	A case-control study of the joint effect of reproductive factors and radiation treatment for first breast cancer and risk of contralateral breast cancer in the WECARE study. Breast, 2020, 54, 62-69.	0.9	3
18	Immunotherapy Advances for Epithelial Ovarian Cancer. Cancers, 2020, 12, 3733.	1.7	24

#	Article	IF	CITATIONS
19	Association between maternal cannabis use and birth outcomes: an observational study. BMC Pregnancy and Childbirth, 2020, 20, 771.	0.9	19
20	Using Precision Medicine with a Neurodevelopmental Perspective to Study Inflammation and Depression. Current Psychiatry Reports, 2020, 22, 87.	2.1	0
21	Seasonality of plasma tryptophan and kynurenine in pregnant mothers with a history of seasonal affective disorder: Vulnerability or adaptation?. World Journal of Biological Psychiatry, 2020, 21, 529-538.	1.3	7
22	Radiation Treatment, <i>ATM</i> , <i>BRCA1/2</i> , and <i>CHEK2</i> *1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer. Journal of the National Cancer Institute, 2020, 112, 1275-1279.	3.0	21
23	Predictors of mammographic density among women with a strong family history of breast cancer. BMC Cancer, 2019, 19, 631.	1.1	5
24	Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool. JNCI Cancer Spectrum, 2019, 3, pkz066.	1.4	8
25	Association of a Pathway-Specific Genetic Risk Score With Risk of Radiation-Associated Contralateral Breast Cancer. JAMA Network Open, 2019, 2, e1912259.	2.8	5
26	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
27	Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. Breast Cancer Research, 2019, 21, 52.	2.2	44
28	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	2.9	52
29	Association of Prepubertal and Adolescent Androgen Concentrations With Timing of Breast Development and Family History of Breast Cancer. JAMA Network Open, 2019, 2, e190083.	2.8	7
30	Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort. International Journal of Cancer, 2019, 145, 370-379.	2.3	9
31	10-year performance of four models of breast cancer risk: a validation study. Lancet Oncology, The, 2019, 20, 504-517.	5.1	116
32	Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC). Breast Cancer Research, 2019, 21, 128.	2.2	27
33	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
34	Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk. Journal of the National Cancer Institute, 2019, 111, 331-334.	3.0	31
35	Serum osteoprotegerin levels and mammographic density among high-risk women. Cancer Causes and Control, 2018, 29, 507-517.	0.8	6
36	Breast cancer family history and allele-specific DNA methylation in the legacy girls study. Epigenetics, 2018, 13, 240-250.	1.3	10

#	Article	IF	CITATIONS
37	Agreement between self-reported and register-based cardiovascular events among Danish breast cancer survivors. Journal of Cancer Survivorship, 2018, 12, 95-100.	1.5	7
38	Comparison of methods to assess onset of breast development in the LEGACY Girls Study: methodological considerations for studies of breast cancer. Breast Cancer Research, 2018, 20, 33.	2.2	9
39	Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study. Journal of Clinical Oncology, 2018, 36, 1513-1520.	0.8	44
40	Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC). Breast Cancer Research, 2018, 20, 132.	2.2	51
41	CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. Breast Cancer Research, 2018, 20, 149.	2.2	11
42	The Ontario Birth Study: A prospective pregnancy cohort study integrating perinatal research into clinical care. Paediatric and Perinatal Epidemiology, 2018, 32, 290-301.	0.8	20
43	The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study. Breast Cancer Research, 2018, 20, 23.	2.2	24
44	A multiâ€wavelength, laserâ€based optical spectroscopy device for breast density and breast cancer risk preâ€screening. Journal of Biophotonics, 2017, 10, 565-576.	1.1	19
45	Dietary isoflavone intake and allâ€cause mortality in breast cancer survivors: The Breast Cancer Family Registry. Cancer, 2017, 123, 2070-2079.	2.0	67
46	Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study. Journal of the National Cancer Institute, 2017, 109, .	3.0	28
47	Alcohol consumption and cigarette smoking in combination: A predictor of contralateral breast cancer risk in the WECARE study. International Journal of Cancer, 2017, 141, 916-924.	2.3	31
48	Predictors of 25-Hydroxyvitamin D Concentration Measured at Multiple Time Points in a Multiethnic Population. American Journal of Epidemiology, 2017, 186, 1180-1193.	1.6	4
49	The dynamic DNA methylation landscape of the mutL homolog 1 shore is altered by MLH1-93G>A polymorphism in normal tissues and colorectal cancer. Clinical Epigenetics, 2017, 9, 26.	1.8	9
50	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
51	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
52	Non-invasive optical spectroscopic monitoring of breast development during puberty. Breast Cancer Research, 2017, 19, 12.	2.2	14
53	Pubertal development in girls by breast cancer family history: the LEGACY girls cohort. Breast Cancer Research, 2017, 19, 69.	2.2	18
54	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. Genetics in Medicine, 2017, 19, 599-603.	1.1	67

#	Article	IF	CITATIONS
55	Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822.	0.9	45
56	Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. Breast Cancer Research, 2017, 19, 83.	2.2	27
57	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. Breast Cancer Research, 2017, 19, 119.	2.2	43
58	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. PLoS Medicine, 2016, 13, e1002105.	3.9	118
59	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 2016, 11, e0160316.	1.1	12
60	The LEGACY Girls Study. Epidemiology, 2016, 27, 438-448.	1.2	24
61	Fineâ€scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 2016, 139, 1303-1317.	2.3	51
62	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174
63	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
64	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes and Control, 2016, 27, 679-693.	0.8	21
65	Body mass index, weight change, and risk of second primary breast cancer in the <scp>WECARE</scp> study: influence of estrogen receptor status of the first breast cancer. Cancer Medicine, 2016, 5, 3282-3291.	1.3	22
66	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Human Molecular Genetics, 2016, 25, 3863-3876.	1.4	33
67	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
68	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
69	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
70	Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study. Breast Cancer Research, 2016, 18, 65.	2.2	33
71	Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for <i>CHEK2</i> *1100delC Carriers. Journal of Clinical Oncology, 2016, 34, 2750-2760.	0.8	152
72	Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC). International Journal of Epidemiology, 2016, 45, 683-692.	0.9	48

#	Article	IF	CITATIONS
73	Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients. BMC Cancer, 2016, 16, 113.	1.1	7
74	Comparison of Clinical, Maternal, and Self Pubertal Assessments: Implications for Health Studies. Pediatrics, 2016, 138, .	1.0	36
75	Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. Cancer Causes and Control, 2016, 27, 459-472.	0.8	63
76	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
77	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	3.0	77
78	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
79	Investigation of geneâ€environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. International Journal of Cancer, 2015, 136, E685-96.	2.3	34
80	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	2.2	26
81	A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density. Breast Cancer Research, 2015, 17, 110.	2.2	19
82	Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair. Obstetrical and Gynecological Survey, 2015, 70, 758-762.	0.2	0
83	SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival. Oncotarget, 2015, 6, 37979-37994.	0.8	20
84	Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry. Breast Cancer Research and Treatment, 2015, 151, 653-660.	1.1	25
85	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	3.0	428
86	Psychosocial Adjustment in School-age Girls With a Family History of Breast Cancer. Pediatrics, 2015, 136, 927-937.	1.0	13
87	Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE study. SpringerPlus, 2015, 4, 825.	1.2	18
88	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	1.4	40
89	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	2.6	76
90	A high-resolution copy-number variation resource for clinical and population genetics. Genetics in Medicine, 2015, 17, 747-752.	1.1	73

#	Article	IF	CITATIONS
91	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis, 2015, 36, 256-271.	1.3	14
92	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	9.4	513
93	Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study. Human Molecular Genetics, 2015, 24, 5356-5366.	1.4	128
94	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	2.6	37
95	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	3.0	56
96	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. Breast Cancer Research, 2015, 17, 18.	2.2	20
97	Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. Cancer Research, 2015, 75, 2457-2467.	0.4	55
98	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nature Genetics, 2015, 47, 1294-1303.	9.4	357
99	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	3.0	99
100	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1680-1691.	1.1	24
101	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	1.4	38
102	The Association between Breast Tissue Optical Content and Mammographic Density in Pre- and Post-Menopausal Women. PLoS ONE, 2015, 10, e0115851.	1.1	17
103	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget, 2015, 6, 7390-7407.	0.8	15
104	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	1.1	49
105	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	1.5	39
106	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nature Communications, 2014, 5, 4051.	5.8	16
107	Correlation of DNA methylation levels in blood and saliva DNA in young girls of the LEGACY Girls study. Epigenetics, 2014, 9, 929-933.	1.3	32
108	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2014, 23, 6096-6111.	1.4	53

#	Article	IF	CITATIONS
109	DNA mismatch repair gene MSH6 implicated in determining age at natural menopause. Human Molecular Genetics, 2014, 23, 2490-2497.	1.4	56
110	Does perceived risk predict breast cancer screening use? Findings from a prospective cohort study of female relatives from the Ontario site of the Breast Cancer Family Registry. Breast, 2014, 23, 482-488.	0.9	10
111	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Human Molecular Genetics, 2014, 23, 1934-1946.	1.4	32
112	A Genome-wide Association Study of Early-Onset Breast Cancer Identifies <i>PFKM</i> as a Novel Breast Cancer Gene and Supports a Common Genetic Spectrum for Breast Cancer at Any Age. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 658-669.	1.1	77
113	Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Geneâ€Environment Interactions. Genetic Epidemiology, 2014, 38, 84-93.	0.6	28
114	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature, 2014, 514, 92-97.	13.7	548
115	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	5.8	105
116	Impact of familial risk and mammography screening on prognostic indicators of breast disease among women from the Ontario site of the Breast Cancer Family Registry. Familial Cancer, 2014, 13, 163-172.	0.9	5
117	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	1.4	12
118	Human Subjects Protection: An Event Monitoring Committee for Research Studies of Girls From Breast Cancer Families. Journal of Adolescent Health, 2014, 55, 352-357.	1.2	5
119	Prospective association of 25(<scp>OH</scp>) <scp>D</scp> with metabolic syndrome. Clinical Endocrinology, 2014, 80, 502-507.	1.2	44
120	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	2.2	14
121	Perceived risk and adherence to breast cancer screening guidelines among women with a familial history of breast cancer: A review of theÂliterature. Breast, 2013, 22, 395-404.	0.9	27
122	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	2.6	98
123	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
124	Total energy intake and breast cancer risk in sisters: the Breast Cancer Family Registry. Breast Cancer Research and Treatment, 2013, 137, 541-551.	1.1	9
125	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. American Journal of Human Genetics, 2013, 92, 489-503.	2.6	201
126	Genome-wide association studies identify four ER negative–specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	9.4	374

#	Article	IF	CITATIONS
127	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	9.4	960
128	Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome–wide interaction study. Endocrine-Related Cancer, 2013, 20, 875-887.	1.6	26
129	Accuracy of Self-Reported Screening Mammography Use: Examining Recall among Female Relatives from the Ontario Site of the Breast Cancer Family Registry. ISRN Oncology, 2013, 2013, 1-9.	2.1	10
130	Evidence of Gene–Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. PLoS Genetics, 2013, 9, e1003284.	1.5	136
131	Risk of Asynchronous Contralateral Breast Cancer in Noncarriers of <i>BRCA1</i> and <i>BRCA2</i> Mutations With a Family History of Breast Cancer: A Report From the Women's Environmental Cancer and Radiation Epidemiology Study. Journal of Clinical Oncology, 2013, 31, 433-439.	0.8	101
132	Diagnostic Chest X-Rays and Breast Cancer Risk before Age 50 Years for BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1547-1556.	1.1	22
133	Genetic Variants in Vitamin D Pathway Genes and Risk of Pancreas Cancer; Results from a Population-Based Case-Control Study in Ontario, Canada. PLoS ONE, 2013, 8, e66768.	1.1	40
134	Common Breast Cancer Susceptibility Variants in <i>LSP1</i> and <i>RAD51L1</i> Are Associated with Mammographic Density Measures that Predict Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1156-1166.	1.1	101
135	19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility Locus. Cancer Research, 2012, 72, 1795-1803.	0.4	100
136	<i>CHEK2</i> *1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer–Specific Death, and Increased Risk of a Second Breast Cancer. Journal of Clinical Oncology, 2012, 30, 4308-4316.	0.8	162
137	Worry Is Good for Breast Cancer Screening: A Study of Female Relatives from the Ontario Site of the Breast Cancer Family Registry. Journal of Cancer Epidemiology, 2012, 2012, 1-9.	0.5	18
138	Accuracy of Self-Reported Breast Cancer Information among Women from the Ontario Site of the Breast Cancer Family Registry. Journal of Cancer Epidemiology, 2012, 2012, 1-11.	0.5	17
139	Variation in Genes Related to Obesity, Weight, and Weight Change and Risk of Contralateral Breast Cancer in the WECARE Study Population. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2261-2267.	1.1	11
140	Risk factors for uncommon histologic subtypes of breast cancer using centralized pathology review in the Breast Cancer Family Registry. Breast Cancer Research and Treatment, 2012, 134, 1209-1220.	1.1	10
141	Reproductive Status at First Diagnosis Influences Risk of Radiation-Induced Second Primary Contralateral Breast Cancer in the WECARE Study. International Journal of Radiation Oncology Biology Physics, 2012, 84, 917-924.	0.4	22
142	Vitamin D Intake Is Negatively Associated with Promoter Methylation of the Wnt Antagonist Gene <i>DKK1</i> in a Large Group of Colorectal Cancer Patients. Nutrition and Cancer, 2012, 64, 919-928.	0.9	54
143	9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1783-1791.	1.1	17
144	Beliefs about optimal age and screening frequency predict breast screening adherence in a prospective study of female relatives from the Ontario Site of the Breast Cancer Family Registry. BMC Public Health, 2012, 12, 518.	1.2	9

#	Article	IF	CITATIONS
145	Solar ultraviolet-B radiation and vitamin D: a cross-sectional population-based study using data from the 2007 to 2009 Canadian Health Measures Survey. BMC Public Health, 2012, 12, 660.	1.2	16
146	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380.	1.1	51
147	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2222-2231.	1.1	27
148	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	3.0	596
149	Association of 25(OH)D and PTH with Metabolic Syndrome and Its Traditional and Nontraditional Components. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 168-175.	1.8	107
150	Promoter methylation of Wnt antagonists <i>DKK1</i> and <i>SFRP1</i> is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. Carcinogenesis, 2011, 32, 741-747.	1.3	74
151	Identification of germline alterations of the mad homology 2 domain of SMAD3 and SMAD4 from the Ontario site of the breast cancer family registry (CFR). Breast Cancer Research, 2011, 13, R77.	2.2	16
152	Influence of perceived breast cancer risk on screening behaviors of female relatives from the Ontario site of the Breast Cancer Family Registry. European Journal of Cancer Prevention, 2011, 20, 255-262.	0.6	23
153	Adherence to breast and ovarian cancer screening recommendations for female relatives from the Ontario site of the Breast Cancer Family Registry. European Journal of Cancer Prevention, 2011, 20, 492-500.	0.6	19
154	STROBE-ME — Illuminating methodological issues for the reporting of molecular epidemiology data. Preventive Medicine, 2011, 53, 388-389.	1.6	2
155	A cross-sectional study of different patterns of oral contraceptive use among premenopausal women and circulating IGF-1: implications for disease risk. BMC Women's Health, 2011, 11, 15.	0.8	20
156	Vitamin D-Related Genetic Variants, Interactions with Vitamin D Exposure, and Breast Cancer Risk among Caucasian Women in Ontario. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1708-1717.	1.1	96
157	Breast Cancer Risk for Noncarriers of Family-Specific <i>BRCA1</i> and <i>BRCA2</i> Mutations: Findings From the Breast Cancer Family Registry. Journal of Clinical Oncology, 2011, 29, 4505-4509.	0.8	38
158	The potential value of sibling controls compared with population controls for association studies of lifestyle-related risk factors: an example from the Breast Cancer Family Registry. International Journal of Epidemiology, 2011, 40, 1342-1354.	0.9	18
159	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortiumâ€. Human Molecular Genetics, 2011, 20, 4693-4706.	1.4	71
160	Ultraviolet Sunlight Exposure During Adolescence and Adulthood and Breast Cancer Risk: A Population-based Case-Control Study Among Ontario Women. American Journal of Epidemiology, 2011, 174, 293-304.	1.6	45
161	Prospective Associations of Vitamin D With Î ² -Cell Function and Glycemia. Diabetes, 2011, 60, 2947-2953.	0.3	124
162	Optical spectroscopy of the breast in premenopausal women reveals tissue variation with changes in age and parity. Medical Physics, 2010, 37, 419-426.	1.6	19

#	Article	IF	CITATIONS
163	Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Research, 2010, 12, R110.	2.2	82
164	Vitamin D association with estradiol and progesterone in young women. Cancer Causes and Control, 2010, 21, 479-483.	0.8	49
165	Vitamin D Intake From Food and Supplements Among Ontario Women Based on the US Block Food Frequency Questionnaire With and Without Modification for Canadian Food Values. Canadian Journal of Public Health, 2010, 101, 318-321.	1.1	12
166	Vitamin D and calcium intakes and breast cancer risk in pre- and postmenopausal women. American Journal of Clinical Nutrition, 2010, 91, 1699-1707.	2.2	69
167	Association of Vitamin D With Insulin Resistance and β-Cell Dysfunction in Subjects at Risk for Type 2 Diabetes. Diabetes Care, 2010, 33, 1379-1381.	4.3	287
168	Family-based association study of IGF1 microsatellites and height, weight, and body mass index. Journal of Human Genetics, 2010, 55, 255-258.	1.1	4
169	Alcohol Intake and Cigarette Smoking and Risk of a Contralateral Breast Cancer: The Women's Environmental Cancer and Radiation Epidemiology Study. American Journal of Epidemiology, 2009, 169, 962-968.	1.6	41
170	Family history of hormonal cancers and colorectal cancer risk: A case ontrol study conducted in Ontario. International Journal of Cancer, 2009, 125, 918-925.	2.3	7
171	Association between IGF1 CA microsatellites and mammographic density, anthropometric measures, and circulating IGF-I levels in premenopausal Caucasian women. Breast Cancer Research and Treatment, 2009, 116, 413-423.	1.1	15
172	Family-based genetic association study of insulin-like growth factor I microsatellite markers and premenopausal breast cancer risk. Breast Cancer Research and Treatment, 2009, 118, 415-424.	1.1	5
173	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature Genetics, 2009, 41, 585-590.	9.4	434
174	Ovarian cysts and breast cancer: results from the Women's Contraceptive and Reproductive Experiences Study. Breast Cancer Research and Treatment, 2008, 109, 157-164.	1.1	7
175	Missense Polymorphisms in the Adenomatous Polyposis Coli Gene and Colorectal Cancer Risk. Diseases of the Colon and Rectum, 2008, 51, 1467-1474.	0.7	12
176	Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer, 2008, 8, 6.	1.1	31
177	Estimation of mammographic density on an interval scale by transillumination breast spectroscopy. Journal of Biomedical Optics, 2008, 13, 064030.	1.4	16
178	Association of Vitamin D Related Information from a Telephone Interview with 25-Hydroxyvitamin D. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 232-238.	1.1	28
179	Vitamin D From Dietary Intake and Sunlight Exposure and the Risk of Hormone-Receptor-Defined Breast Cancer. American Journal of Epidemiology, 2008, 168, 915-924.	1.6	47
180	Association between Transillumination Breast Spectroscopy and Quantitative Mammographic Features of the Breast. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1043-1050.	1.1	39

#	Article	IF	CITATIONS
181	MSH2 â^'118T>C and MSH6 â^'159C>T promoter polymorphisms and the risk of colorectal cancer. Carcinogenesis, 2007, 28, 2575-2580.	1.3	22
182	Vitamin D and Reduced Risk of Breast Cancer: A Population-Based Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 422-429.	1.1	153
183	MLH1 -93G>A Promoter Polymorphism and the Risk of Microsatellite-Unstable Colorectal Cancer. Journal of the National Cancer Institute, 2007, 99, 463-474.	3.0	116
184	Medical radiation exposure and breast cancer risk: Findings from the Breast Cancer Family Registry. International Journal of Cancer, 2007, 121, 386-394.	2.3	53
185	Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis. BMC Cancer, 2007, 7, 99.	1.1	21
186	Methodological issues in detecting gene-gene interactions in breast cancer susceptibility: a population-based study in Ontario. BMC Medicine, 2007, 5, 22.	2.3	39
187	Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study. Breast Cancer Research and Treatment, 2007, 105, 69-80.	1.1	53
188	Alcohol metabolism, alcohol intake, and breast cancer risk: a sister-set analysis using the Breast Cancer Family Registry. Breast Cancer Research and Treatment, 2007, 106, 281-288.	1.1	24
189	BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1863-1870.	1.1	115
190	SNP-SNP interactions in breast cancer susceptibility. BMC Cancer, 2006, 6, 114.	1.1	146
191	An inverse association between ovarian cysts and breast cancer in the breast cancer family registry. International Journal of Cancer, 2006, 118, 197-202.	2.3	9
192	The CHEK2*1100delC Allelic Variant and Risk of Breast Cancer: Screening Results from the Breast Cancer Family Registry. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 348-352.	1.1	46
193	No Association Between 25-Hydroxyvitamin D and Mammographic Density. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1988-1992.	1.1	37
194	No Increased Risk of Breast Cancer Associated with Alcohol Consumption among Carriers of BRCA1 and BRCA2 Mutations Ages <50 Years. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1565-1567.	1.1	42
195	ADH3 genotype, alcohol intake and breast cancer risk. Carcinogenesis, 2006, 27, 840-847.	1.3	59
196	Comparison of Self-reported Lifetime Sun Exposure with Two Methods of Cutaneous Microtopography. American Journal of Epidemiology, 2006, 165, 222-230.	1.6	6
197	Accuracy of breast screening among women with and without a family history of breast and/or ovarian cancer. Breast Cancer Research and Treatment, 2005, 90, 299-305.	1.1	14
198	Oral Contraceptive Use and Risk of Early-Onset Breast Cancer in Carriers and Noncarriers of BRCA1 and BRCA2 Mutations. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 350-356.	1.1	133

#	Article	IF	CITATIONS
199	Light and Exercise and Melatonin Production in Women. American Journal of Epidemiology, 2005, 162, 1114-1122.	1.6	36
200	Genetic Variants of GPX1 and SOD2 and Breast Cancer Risk at the Ontario Site of the Breast Cancer Family Registry. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 146-149.	1.1	79
201	Association Between Biallelic and Monoallelic Germline MYH Gene Mutations and Colorectal Cancer Risk. Journal of the National Cancer Institute, 2004, 96, 1631-1634.	3.0	239
202	The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Research, 2004, 6, R375-89.	2.2	255
203	Ethnicity, but not cancer family history, is related to response to a population-based mailed questionnaire. Annals of Epidemiology, 2004, 14, 36-43.	0.9	16
204	Polymorphisms XRCC1-R399Q and XRCC3-T241M and the risk of breast cancer at the Ontario site of the Breast Cancer Family Registry. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 583-91.	1.1	33
205	Characteristics Associated with Participation at Various Stages at the Ontario Site of the Cooperative Family Registry for Breast Cancer Studies. Annals of Epidemiology, 2002, 12, 27-33.	0.9	32
206	HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer, 2002, 95, 2068-2075.	2.0	61
207	The Cooperative Familial Registry for Breast Cancer Studies. Journal of Clinical Epidemiology, 2001, 54, 93-98.	2.4	20
208	Modeling Complex Disease with Demographic and Environmental Covariates and a Candidate Gene Marker. Genetic Epidemiology, 2001, 21, S423-S428.	0.6	2
209	Frequency of p53 Mutations in Breast Carcinomas From Ashkenazi Jewish Carriers of BRCA1 Mutations. Journal of the National Cancer Institute, 1999, 91, 469-473.	3.0	94
210	Putting the Risk of Breast Cancer in Perspective. New England Journal of Medicine, 1999, 340, 141-144.	13.9	98
211	An assessment of the influence of clinical breast examination reports on the interpretation of mammograms in a breast screening program Breast Cancer Research and Treatment, 1998, 48, 65-71.	1.1	9
212	Parental Occupational Exposure and the Risk of Testicular Cancer in Ontario. Journal of Occupational and Environmental Medicine, 1997, 39, 333-338.	0.9	26
213	Occupation and Risk of Germ Cell Testicular Cancer by Histologic Type in Ontario. Journal of Occupational and Environmental Medicine, 1996, 38, 884-890.	0.9	22
214	Maternal acetaminophen use and cognitive development at 4 years: the Ontario Birth Study. Pediatric Research, 0, , .	1.1	1